Show simple item record

dc.contributor.authorde Bono, J
dc.contributor.authorChowdhury, S
dc.contributor.authorFeyerabend, S
dc.contributor.authorElliott, Tony
dc.contributor.authorGrande, E
dc.contributor.authorMelhem-Bertrandt, A
dc.contributor.authorBaron, B
dc.contributor.authorHirmand, M
dc.contributor.authorWerbrouck, P
dc.contributor.authorFizazi, K
dc.date.accessioned2017-09-22T15:38:42Z
dc.date.available2017-09-22T15:38:42Z
dc.date.issued2017-08-22
dc.identifier.citationAntitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for >/=24 weeks in Europe. 2017 Eur Urolen
dc.identifier.issn1873-7560
dc.identifier.pmid28844372
dc.identifier.doi10.1016/j.eururo.2017.07.035
dc.identifier.urihttp://hdl.handle.net/10541/620569
dc.description.abstractEnzalutamide and abiraterone acetate plus prednisone, which target the androgen receptor axis, have expanded the treatment of advanced prostate cancer. Retrospective analyses suggest some cross-resistance between these two drugs when used sequentially, but robust, prospective studies have not yet been reported.
dc.language.isoenen
dc.rightsArchived with thanks to European urologyen
dc.titleAntitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for >/=24 weeks in Europe.en
dc.typeArticleen
dc.contributor.departmentThe Institute of Cancer Research, London, UKen
dc.identifier.journalEuropean Urologyen
html.description.abstractEnzalutamide and abiraterone acetate plus prednisone, which target the androgen receptor axis, have expanded the treatment of advanced prostate cancer. Retrospective analyses suggest some cross-resistance between these two drugs when used sequentially, but robust, prospective studies have not yet been reported.


Files in this item

This item appears in the following Collection(s)

Show simple item record